Posted On: 02/16/2016 11:37:25 AM
Post# of 30074
Todd Sherer (CEO of MJFF) is on the panel with GC and said this about Eltoprazine in 2012:
Perhaps he will throw us a bone to get the eltoprazine trials up and running again.
Quote:
Positive data from an early clinical trial funded by MJFF demonstrating that a drug targeting a neurotransmitter called serotonin (often associated with depression) holds potential as a dyskinesia therapy. The next step for a team of researchers including Anders Björklund, MD, PhD, from Lund University, and contract research organization PsychoGenics, will be to design a larger-scale study to better understand how well this drug, called eltoprazine, might work in treating dyskinesia.
Quote:
The Michael J Fox Foundation CEO, Todd Sherer, said: "The results presented by PsychoGenics and Dr Bjorklund show early promise in finding a potential treatment for dyskinesia and we look forward to working with this team to drive their program forward."
Quote:
“Dyskinesia is a top priority for the Foundation because of its impact on the quality of life of people living with Parkinson’s disease,” said Todd Sherer, PhD, CEO of The Michael J. Fox Foundation. “The results presented by PsychoGenics and Dr. Bjorklund show early promise in finding a potential treatment for dyskinesia, and we look forward to working with this team to drive their program forward.”
Perhaps he will throw us a bone to get the eltoprazine trials up and running again.
(4)
(0)
